Coronary stent implantation in patients committed to long-term oral anticoagulation therapy: Successfully navigating the treatment options

Chest

Volumn 139, Issue 5, 2011, Pages 981-987

  Rubboli, Andrea ^a   Kovacic, Jason C ^b   Mehran, Roxana ^b   Lip, Gregory Y H ^c  

^a MAGGIORE HOSPITAL   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART DEATH; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; NOTE; OUTCOMES RESEARCH; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; STENT THROMBOSIS; STROKE; THROMBOEMBOLISM;

EID: 79955876172     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-2719     Document Type: Note

References (36)

1. Lip GY, Huber K, Andreotti F, et al; European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010;103(1):13-28.
2. Rubboli A, Halperin JL, Airaksinen KE, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med. 2008;40( 6):428-436.
3. Dewilde W, Berg JT. Design and rationale of the WOEST trial:What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST) ? Am Heart J. 2009;158(5):713-718.
4. Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007;28(6):726-732. (Pubitemid 46439228)
5. Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374(9706):1967-1974.
6. Hansen ML, Sørensen R, Clausen MC, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433-1441.
7. Orford JL, Fasseas P, Melby S, et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J. 2004;147(3):463-467. (Pubitemid 38880866)
8. Mattichak SJ, Reed PS, Gallagher MJ, Boura JA, O'Neill WW, Kahn JK. Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction. J Interv Cardiol. 2005;18(3):163-166. (Pubitemid 40942726)
9. Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol. 2006;18(4):162-164. (Pubitemid 44576090)
10. Porter A, Konstantino Y, Iakobishvili Z, Shachar L, Battler A, Hasdai D. Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006;68(1):56-61. (Pubitemid 44024462)
11. Lip GYH, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest. 2006;130(6):1823-1827. (Pubitemid 46033440)
12. DeEugenio D, Kolman L, DeCaro M, et al. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy. 2007;27(5):691-696. (Pubitemid 46700961)
13. Rubboli A, Colletta M, Herzfeld J, Sangiorgio P, Di Pasquale G. Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention. Coron Artery Dis. 2007;18(3):193-199. (Pubitemid 46608497)
14. Nguyen MC, Lim YL, Walton A, et al. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: Is it safe and effective to use just one antiplatelet agent? Eur Heart J. 2007;28(14):1717-1722.
15. Wang TY, Robinson LA, Ou F-S, et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J. 2008;155(2):361-368.
16. Ruiz-Nodar JM, Marin F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008;51(8):818-825. (Pubitemid 351255616)
17. Rogacka R, Chieffo A, Michev I, et al. Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. J Am Coll Cardiol Intv. 2008;1(1):56-61. (Pubitemid 351447185)
18. Valencia J, Mainar V, Bordes P, Pineda J, Gómez S, Sogorb F. Observance of antiplatelet therapy after stent implantation in patients under chronic oral anticoagulant treatment. J Interv Cardiol. 2008;21(3):218-224. (Pubitemid 351703983)
19. Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008;102(12):1618-1623.
20. Ruiz-Nodar JM, Marín F, Sánchez-Payá J, et al. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. Eur Heart J. 2009;30(8):932-939.
21. Gilard M, Blanchard D, Helft G, et al; STENTICO Investigators . Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]). Am J Cardiol. 2009;104(3):338-342.
22. Hälg C, Brunner-La Rocca HP, Kaiser C, et al; BASKET Investigators. Early and late increased bleeding rates after angioplasty and stenting due to combined antiplatelet and anticoagulant therapy. EuroIntervention. 2009;5(4):425-431.
23. Karjalainen PP, Vikman S, Niemelä M, et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J. 2008;29(8):1001-1010. (Pubitemid 351844686)
24. Lahtela H, Karjalainen PP, Niemelä M, et al. Are glycoprotein inhibitors safe during percutaneous coronary intervention in patients on chronic warfarin treatment? Thromb Haemost. 2009;102(6):1227-1233.
25. Rubboli A, Colletta M, Valencia J, et al; WARfarin and Coronary STENTing (WAR-STENT) Study Group. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. J Interv Cardiol. 2009;22(4):390-397.
26. Rubboli A, Halperin JL. Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Thromb Haemost. 2008;100(5):752-753.
27. Roldán V, Marín F. Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody. Thromb Haemost. 2008;100(5):754-755.
28. Gao F, Zhou YJ, Wang ZJ, et al. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation. Circ J. 2010;74(4):701-708.
29. Sambola A, Ferreira-González I, Angel J, et al. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study. Heart. 2009;95(18):1483-1488.
30. Camm AJ, Kirchhof P, Lip GY, et al; European Heart Rhythm Association;European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-2429.
31. Roy P, Bonello L, Torguson R, et al. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol. 2008;102(12):1614-1617.
32. Lemesle G, Delhaye C, Bonello L, de Labriolle A, Waksman R, Pichard A. Stent thrombosis in 2008: definition, predictors, prognosis and treatment. Arch Cardiovasc Dis. 2008;101(11-12):769-777.
33. Fauchier L, Lip GY. Guidelines for antithrombotic therapy in atrial fibrillation: understanding the reasons for nonadherence and moving forwards with simplifying risk stratification for stroke and bleeding. Europace. 2010;12( 6):761-763.
34. Kushner FG, Hand M, Smith SC Jr, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Associa tion Task Force on Practice Guidelines. Circulation. 2009;120(22):2271-2306.
35. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
36. Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.